TSCAN THERAPEUTICS, INC. Operating Cash Flow
TSCAN THERAPEUTICS, INC. (TCRX) reported Operating Cash Flow of -$51.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$27.54M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$24.28M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$32.00M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$32.46M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$135.32M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$110.82M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$61.36M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$66.50M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$27.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$51.81M 10-Q · filed 2026-08-12 | -$83.82M derived: sum of 3 quarters · filed 2026-08-12 | -$116.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$24.28M 10-Q · filed 2026-05-06 | -$56.28M derived: sum of 2 quarters · filed 2026-05-06 | -$88.75M derived: sum of 3 quarters · filed 2026-05-06 | -$122.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$32.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$64.47M derived: sum of 2 quarters · filed 2026-03-04 | -$97.73M derived: sum of 3 quarters · filed 2026-08-12 | -$135.32M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$32.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$65.73M derived: sum of 2 quarters · filed 2026-08-12 | -$103.32M 10-Q · filed 2025-11-12 | -$130.73M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$33.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$70.85M 10-Q · filed 2026-08-12 | -$98.27M derived: sum of 3 quarters · filed 2026-08-12 | -$126.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$37.59M 10-Q · filed 2026-05-06 | -$65.00M derived: sum of 2 quarters · filed 2026-05-06 | -$92.92M derived: sum of 3 quarters · filed 2026-05-06 | -$119.14M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$27.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$55.33M derived: sum of 2 quarters · filed 2026-03-04 | -$81.56M derived: sum of 3 quarters · filed 2026-03-04 | -$110.82M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$27.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$54.14M derived: sum of 2 quarters · filed 2025-11-12 | -$83.41M 10-Q · filed 2025-11-12 | -$107.18M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$26.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$55.49M 10-Q · filed 2025-08-12 | -$79.26M derived: sum of 3 quarters · filed 2025-08-12 | -$71.24M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$29.27M 10-Q · filed 2025-05-06 | -$53.03M derived: sum of 2 quarters · filed 2025-05-06 | -$45.02M derived: sum of 3 quarters · filed 2025-05-06 | -$67.04M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$23.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$15.75M derived: sum of 2 quarters · filed 2025-03-05 | -$37.77M derived: sum of 3 quarters · filed 2025-03-05 | -$61.36M 10-K · filed 2025-03-05 |
| 2023-09-30 | $8.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$14.01M derived: sum of 2 quarters · filed 2024-11-12 | -$37.59M 10-Q · filed 2024-11-12 | -$53.60M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$22.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$45.61M 10-Q · filed 2024-08-12 | -$61.62M derived: sum of 3 quarters · filed 2024-08-12 | -$78.62M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$23.59M 10-Q · filed 2024-05-13 | -$39.60M derived: sum of 2 quarters · filed 2024-05-13 | -$56.60M derived: sum of 3 quarters · filed 2024-05-13 | -$69.97M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$16.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$33.01M derived: sum of 2 quarters · filed 2024-03-06 | -$46.38M derived: sum of 3 quarters · filed 2024-03-06 | -$66.50M 10-K · filed 2024-03-06 |
| 2022-09-30 | -$17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$30.37M derived: sum of 2 quarters · filed 2023-11-09 | -$50.49M 10-Q · filed 2023-11-09 | -$64.87M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$13.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$33.49M 10-Q · filed 2023-08-10 | -$47.87M derived: sum of 3 quarters · filed 2023-08-10 | -$61.51M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$20.12M 10-Q · filed 2023-05-10 | -$34.50M derived: sum of 2 quarters · filed 2023-05-10 | -$48.14M derived: sum of 3 quarters · filed 2023-05-10 | -$58.84M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$14.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$28.02M derived: sum of 2 quarters · filed 2023-03-08 | -$38.72M derived: sum of 3 quarters · filed 2023-03-08 | -$48.68M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$13.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$24.34M derived: sum of 2 quarters · filed 2022-11-09 | -$34.30M 10-Q · filed 2022-11-09 | -$41.65M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$10.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$20.66M 10-Q · filed 2022-08-10 | -$28.01M derived: sum of 3 quarters · filed 2022-08-10 | -$33.80M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$9.96M 10-Q · filed 2022-05-12 | -$17.31M derived: sum of 2 quarters · filed 2022-05-12 | -$23.10M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$7.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$13.14M derived: sum of 2 quarters · filed 2022-03-09 | -$3.02M 10-K · filed 2022-03-09 | |
| 2020-09-30 | -$5.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.33M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $10.12M 10-Q · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |